RSSL is committed to constantly expanding its expertise to support the development of innovative therapeutics at the cutting-edge of the pharmaceutical industry.
As part of this commitment, RSSL can provide analytical testing and method development support for inhaled pharmaceutical and biopharmaceutical drug products.
Drug delivery via the inhalation route is a growing area of interest within the pharmaceutical industry as it is capable of providing localised and systemic drug delivery to the respiratory mucosa.
Over recent years, nasally inhaled vaccines have become a popular area of research. This is because, in addition to improving ease of use, they have the potential to improve global vaccine accessibility by reducing the need for trained medical staff for vaccine administration.
For successful drug delivery via the inhalation route, a drug candidate has to undergo various drug development phases. Utilising our extensive analytical testing facilities and equipment, our skilled teams can develop and validate analytical methods for both inhaled drug delivery platforms and nasal drug products.
To provide continuous support throughout nasal drug development, RSSL can provide:
RSSL also has the expertise and equipment to support the development of inhaled drug delivery platforms such as pressurised metered dose inhalers (pMDI) and dry-powder inhalers (DPI). Analyses RSSL can offer include:
